Retatrutide (LY3437943)

Retatrutide, formally designated LY3437943 and developed by Eli Lilly and Company, is a synthetic 39-amino acid lipidated peptide engineered as a first-in-class triple hormone receptor agonist, simultaneously activating the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). It differs from native gut hormones and from existing dual agonists like tirzepatide through three deliberate structural modifications and one lipidation: position 2 and position 20 carry 2-aminoisobutyric acid (Aib) substitutions that resist dipeptidyl peptidase-4 (DPP-4) enzymatic cleavage; position 13 carries an alpha-methylleucine modification for additional proteolytic stability; and position 17 carries a lysine residue conjugated to a C20 fatty diacid via an AEEA-gamma-Glu spacer chain, enabling reversible albumin binding and establishing the once-weekly pharmacokinetic profile. These modifications yield a molecular weight of approximately 4,731 Daltons. Retatrutide binds its three targets with differential affinity — highest potency at the human GIP receptor (EC50: 0.064 nM), intermediate at the GLP-1 receptor (EC50: 0.775 nM), and lowest at the glucagon receptor (EC50: 5.79 nM) — a calibration designed to maximize metabolic benefit while preventing glucagon-driven hyperglycemia from dominating the pharmacological profile.

These structural choices produce three synergistic pharmacological consequences: GLP-1R activation suppresses appetite and drives glucose-dependent insulin secretion; GIPR activation amplifies insulin output and modulates lipid homeostasis; and GCGR activation — the key differentiator from any approved therapy — drives hepatic lipolysis, thermogenesis, and increased basal energy expenditure, producing active fat combustion independent of appetite suppression. The result is a compound that, in its Phase 2 pivotal trial, produced a mean 24.2% body weight reduction at 48 weeks in adults with obesity — a magnitude historically associated with bariatric surgery — and a mean 28.7% body weight reduction at 68 weeks in Phase 3 TRIUMPH-4 data presented in December 2025.

Retatrutide is currently in active Phase 3 clinical development under Eli Lilly’s TRIUMPH program across seven trials. It carries no FDA approval as of May 2026; no New Drug Application (NDA) has been submitted, and earliest possible approval is broadly projected for late 2026 to 2027. It is not listed on any FDA 503A/503B bulk compounding substance list, has not been approved in any country, and is available only as an unregulated research-use compound through peptide vendors. Its GI adverse event profile — predominantly nausea, vomiting, diarrhea, and constipation — is consistent with the incretin drug class and is dose-dependent.

Retatrutide operates through simultaneous, synergistic engagement of three distinct G-protein coupled receptors expressed broadly across the gut, pancreas, liver, adipose tissue, central nervous system, and kidney. Unlike sequential or additive pharmacology, its triple agonism produces a coordinated metabolic reprogramming that no single or dual agonist can fully replicate. Each receptor arm contributes a distinct and non-redundant physiological effect; the balance between them is engineered rather than incidental.

GLP-1 Receptor Agonism — Appetite Suppression and Glycemic Control

The GLP-1R is the foundational target of the entire incretin mimetic drug class, expressed in pancreatic beta-cells, intestinal mucosa, hypothalamus, brainstem, and kidney:

• GLP-1R activation in pancreatic beta-cells stimulates glucose-dependent insulin secretion — insulin release occurs only in the presence of elevated blood glucose, substantially reducing hypoglycemia risk relative to sulfonylureas or basal insulin.

• GLP-1R signaling in the hypothalamus (arcuate nucleus) and brainstem (area postrema, nucleus tractus solitarius) suppresses appetite and induces satiety, reducing total caloric intake independent of palatability or food availability.

• Peripheral GLP-1R agonism delays gastric emptying, flattening postprandial glucose excursions and prolonging satiety signaling after meals.

• GLP-1R activation suppresses glucagon secretion from pancreatic alpha-cells, further stabilizing postprandial glucose levels.

• Emerging data suggest GLP-1R agonism reduces inflammation by attenuating macrophage activity, a mechanism potentially relevant to cardiovascular and hepatic benefit independent of weight loss.

GIP Receptor Agonism — Incretin Amplification

The GIPR is the second incretin target, expressed primarily in pancreatic beta-cells, adipose tissue, bone, and CNS reward circuits:

• GIPR stimulation potentiates insulin secretion synergistically with GLP-1R activation, producing greater total insulin output than either receptor alone.

• GIPR agonism in adipose tissue and CNS pathways contributes to appetite regulation, bone density maintenance, and lipid homeostasis.

• Despite historical concern that GIP signaling might promote adipogenesis and fat storage, retatrutide’s combined GIPR + GLP-1R + GCGR profile produces net fat loss, mirroring the tirzepatide observation that dual GLP-1/GIP agonism outperforms GLP-1 monotherapy in weight reduction.

• GIP receptors, when activated, display increased intracellular calcium, arachidonic acid release, and adenylyl cyclase activation — a signaling cascade that, when balanced against GLP-1R and GCGR co-activation, produces coordinated anabolic-catabolic metabolic recalibration.

Glucagon Receptor Agonism — Energy Expenditure and Hepatic Lipolysis

GCGR activation is retatrutide’s most pharmacologically distinctive contribution and the primary driver of its superior weight loss relative to all approved GLP-1 and GLP-1/GIP agents:

• Glucagon receptor agonism in hepatocytes stimulates glycogenolysis and gluconeogenesis, raising hepatic glucose output — but this hyperglycemic effect is counterbalanced by simultaneous GLP-1R- and GIPR-driven insulin secretion, producing glucose neutrality in clinical practice.

• Hepatic lipolysis and beta-oxidation are directly stimulated by GCGR signaling, driving mobilization and combustion of stored triglycerides independent of caloric restriction.

• GCGR agonism increases basal thermogenesis and energy expenditure — the mechanism by which retatrutide produces active fat burning beyond passive appetite reduction, differentiating it from currently approved agents.

• Glucagon reduces hepatic de novo lipogenesis, decreasing fat synthesis and showing particular promise in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

• Glucagon receptor activation in adipose tissue inhibits lipogenesis and stimulates lipolysis, generating non-esterified fatty acids that are then oxidized for energy.

Albumin Binding and Half-Life Engineering

Retatrutide’s once-weekly pharmacokinetic profile is achieved through deliberate structural engineering rather than inherent peptide stability:

• The C20 fatty diacid side chain at K17, linked via an AEEA-gamma-Glu spacer, enables reversible, non-covalent albumin binding, slowing renal clearance and proteolytic degradation and extending the effective half-life to approximately 6 days, supporting once-weekly subcutaneous dosing.

• The Aib substitutions at positions 2 and 20 confer resistance to DPP-4 cleavage, the primary enzymatic degradation pathway for endogenous GLP-1 and GIP, which have half-lives of only 1–2 minutes in native form.

• The alpha-methylleucine modification at position 13 provides additional sterically based proteolytic stability.

• Maximum plasma concentration is achieved within 12–72 hours after subcutaneous injection; retatrutide undergoes primarily hepatic metabolism with no cytochrome P450 enzyme interactions, a clinically important property for a drug likely to be co-administered with statins, antihypertensives, and other metabolic medications.

Receptor Balance: The Pharmacological Engineering Challenge

Designing a functional triple agonist requires precise calibration. Native glucagon is potently hyperglycemic; unbalanced GCGR activation would produce unacceptable fasting and postprandial glucose elevation. Retatrutide resolves this through intentional differential affinity engineering:

• Highest binding affinity at GIPR (EC50 0.064 nM) drives maximal incretin-mediated insulin release, providing the glucose-stabilizing counterweight to glucagon.

• GLP-1R affinity (EC50 0.775 nM) provides satiety, gastric emptying delay, and additional insulin amplification.

• GCGR affinity (EC50 5.79 nM) — the lowest of the three — is deliberately submaximal, ensuring thermogenic and lipolytic benefits without clinically significant hyperglycemia.

• This represents a form of intentional “unimolecular polypharmacology” — a single molecule engineered to produce coordinated, mechanistically complementary effects across three receptor pathways simultaneously, something not achievable by combining three separate agonists at independent doses.

Retatrutide has a substantially richer human clinical evidence base than most investigational peptides, owing to Eli Lilly’s active and well-resourced development program. The evidence hierarchy spans in vitro receptor characterization, Phase 1 safety and pharmacokinetic studies, pivotal Phase 2 randomized controlled trials published in the New England Journal of Medicine, preclinical animal efficacy data, and ongoing Phase 3 TRIUMPH trials. It is important to distinguish evidence specific to retatrutide from broader evidence for the incretin drug class; retatrutide has its own published human trial data that is unusually robust for an unapproved compound.

Preclinical Animal Studies

Retatrutide’s preclinical profile was characterized in several well-designed animal models prior to human trials:

– Urva et al. demonstrated that retatrutide produced dose-dependent gastric emptying delay and superior weight loss in obese C57/B16 mice compared to semaglutide, a glucagon receptor agonist, and the combination of both — with 10 nmol/kg retatrutide achieving greater weight reduction over 10 days than any comparator arm¹

– Ma et al. showed that in db/db diabetic mice, retatrutide outperformed both liraglutide and tirzepatide in reducing body weight, HbA1c, total cholesterol, triglycerides, LDL, and liver enzyme levels (ALT/AST), and demonstrated lower expression of inflammatory and fibrotic mediators — highlighting potential renal and hepatic protective effects¹

– Jall et al. demonstrated reversal of steatohepatitis in female mice maintained on a high-fat, high-sugar diet, with the triple agonist improving glucose tolerance, reducing body and fat mass, improving lipid profiles, and in some female mice producing complete histological resolution of steatohepatitis¹

• Across animal models, retatrutide consistently outperformed single and dual agonists on both metabolic and hepatic endpoints, establishing the pharmacological rationale for human investigation

Phase 1 Human Safety and Pharmacokinetic Studies

– Coskun et al. (Phase 1, Singapore) enrolled 47 healthy individuals and characterized retatrutide’s pharmacokinetic profile: maximum concentration was achieved within 12–72 hours; mean half-life was approximately 6 days; body weight decreased at all dose levels except 0.1 mg; peak weight loss occurred at 3–6 mg³

– Urva et al. conducted a Phase 1b multiple-ascending dose study in type 2 diabetic patients receiving retatrutide weekly (0.5 to 12 mg) or comparators including dulaglutide 1.5 mg, confirming gastric emptying delay, dose-dependent glycemic control, and a GI-predominant adverse event profile consistent with the GLP-1 drug class³

– No dose-limiting hypoglycemia was observed in Phase 1, consistent with the glucose-dependent insulin secretion mechanism³

Phase 2 Obesity Trial — New England Journal of Medicine (2023)

The landmark Phase 2 randomized controlled trial published in the NEJM in 2023 (Jastreboff et al.) remains the most cited efficacy benchmark for retatrutide:⁶

• 338 adults with obesity (BMI ≥30 or ≥27 with a weight-related comorbidity) were randomized to once-weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) or placebo for 48 weeks
• At 24 weeks, mean body weight change ranged from −7.2% (1 mg) to −17.5% (12 mg) vs. −1.6% in placebo
• At 48 weeks, mean body weight change reached −8.7% (1 mg) and −24.2% (12 mg) vs. −2.1% in placebo — a magnitude historically associated with bariatric surgical procedures
• At 48 weeks, in the 12 mg arm: 100% of participants lost ≥5% of body weight; 93% lost ≥10%; 83% lost ≥15%
• The weight loss trajectory had not plateaued at 48 weeks in the highest dose group, suggesting potential for continued efficacy with extended treatment duration
• Secondary metabolic endpoints — waist circumference, systolic blood pressure, fasting insulin, and triglycerides — all showed statistically significant improvement across dose groups

Phase 2 Type 2 Diabetes Trial — New England Journal of Medicine (2023)

Rosenstock et al. conducted a parallel Phase 2 RCT in adults aged 18–75 with type 2 diabetes (HbA1c 7.0–10.5%, BMI 25–50 kg/m²):⁵

• Participants were randomized to retatrutide maintenance doses of 0.5, 4, 8, or 12 mg, placebo, or dulaglutide 1.5 mg (active comparator)
• At 24 weeks, HbA1c reductions ranged from −0.43% (0.5 mg) to −2.02% (12 mg) vs. −0.01% placebo and −1.41% dulaglutide
• At 36 weeks, body weight decreased by up to −16.94% (12 mg) vs. −3.00% placebo and −2.02% dulaglutide
• Retatrutide achieved significantly greater HbA1c reduction than the active comparator (dulaglutide 1.5 mg) in the 8 mg and 12 mg groups
• No severe hypoglycemia events were observed in active treatment arms across the trial duration

Phase 2 Hepatic Steatosis Trial (2024)

Sanyal et al. evaluated retatrutide’s effects on liver fat content in a pre-specified Phase 2 substudy:⁹

• 98 patients with ≥10% liver fat content (by MRI-PDFF) were randomized to retatrutide (1, 4, 8, or 12 mg) or placebo for 48 weeks
• At 24 weeks, mean relative change in liver fat ranged from −42.9% (1 mg) to −82.4% (12 mg) vs. +0.3% in placebo
• Normal liver fat (<5%) was achieved at 24 weeks in 27% (1 mg), 52% (4 mg), 79% (8 mg), and 86% (12 mg) of participants vs. 0% in placebo
• At 48 weeks, the 12 mg dose achieved a mean relative liver fat reduction of −86.0%, with 93% of participants in this arm achieving normal liver fat content
• Liver fat reduction correlated with reductions in abdominal fat, improved insulin sensitivity, and improved lipid metabolism — suggesting direct hepatic benefit beyond weight loss alone

Phase 3 TRIUMPH Program — Emerging Data

Eli Lilly’s Phase 3 TRIUMPH program encompasses seven trials evaluating retatrutide across obesity, type 2 diabetes, cardiovascular outcomes, obstructive sleep apnea, and osteoarthritis:^7,8

• TRIUMPH-1: Enrolling approximately 2,300 adults with obesity without T2DM; primary completion estimated mid-2026
• TRIUMPH-2: Evaluating retatrutide in approximately 1,000 adults with T2DM and obesity, including a subset with obstructive sleep apnea
• TRIUMPH-3: Cardiovascular outcomes trial in obese patients with established cardiovascular disease (prior MI, stroke, or peripheral arterial disease); enrolling approximately 1,800 patients
• TRIUMPH-4 (knee osteoarthritis + obesity): Data presented at ACR Convergence in December 2025 demonstrated 7% mean body weight reduction at 68 weeks — the largest weight loss documented in any Phase 3 pharmacological trial — alongside clinically and statistically significant reductions in knee pain, stiffness, and functional limitation scores
• A dedicated cardiovascular outcomes trial (CVOT) analogous to the SELECT trial for semaglutide is anticipated; MACE data are not yet available as of May 2026

Clinical Development

Retatrutide is an investigational compound in active late-stage clinical development by Eli Lilly:

– Native GLP-1 agonists (semaglutide/Ozempic, Wegovy) and a GLP-1/GIP dual agonist (tirzepatide/Mounjaro, Zepbound) are FDA-approved; retatrutide is the only triple agonist in Phase 3 and has not yet been submitted for approval⁸

– No NDA has been submitted to the FDA as of May 2026; earliest possible approval is broadly projected for late 2026 to 2027, contingent on successful Phase 3 completion and regulatory review⁸

• Phase 3 TRIUMPH trials collectively represent one of the most expansive clinical development packages in obesity pharmacotherapy, spanning at least 7,000 enrolled participants across multiple indications
• Retatrutide has no approved therapeutic indication in any country globally as of May 2026

Regulatory Status

**FDA (United States):** Retatrutide is not approved for any human therapeutic use. It is not listed on the FDA’s 503A/503B Category 1 or Category 2 bulk compounding substance lists, meaning it has not been evaluated for compounding eligibility and cannot be legally compounded for patient use. Selling or promoting retatrutide for human use outside of an approved clinical trial constitutes marketing an unapproved new drug under 21 U.S.C. § 331.⁸

WADA: Retatrutide is not currently listed on the WADA Prohibited List by name; however, it falls under the broad prohibition on GLP-1 receptor agonists and related peptide hormones under Section S2 of the WADA 2025/2026 Prohibited List if used for prohibited performance enhancement purposes. Athletes subject to anti-doping rules should confirm current status with their national anti-doping organization before use in any context.

International: No regulatory authority — EMA, Health Canada, TGA, or otherwise — has approved retatrutide for any indication. Its availability is currently limited to clinical trial enrollment and unregulated research chemical suppliers, the latter of which carry significant quality and safety concerns.

Safety Profile

Retatrutide’s human safety data derives from controlled Phase 1 and Phase 2 clinical trials — a more robust evidence base than most investigational research peptides, but still limited compared to the post-approval pharmacovigilance data available for semaglutide or tirzepatide. Long-term safety, cardiovascular outcomes, and rare adverse event incidence remain under evaluation in ongoing Phase 3 trials.

Established Adverse Effects from Phase 1 and Phase 2 Human Trials

Adverse effects observed in controlled clinical trials are consistent with the incretin drug class and are dose-dependent:^3,6

• Nausea: The most common adverse event across all dose groups; highest incidence at dose escalation
• Vomiting: Dose-dependent; managed through gradual dose titration protocols
• Diarrhea: Reported across active dose groups; typically transient and mild-to-moderate in severity
• Constipation: Less common than nausea but reported at meaningful frequency
• Transient ALT elevation: A temporary increase in alanine aminotransferase was observed in some participants; clinical significance under evaluation in Phase 3
• Increased resting heart rate: An incretin class effect observed with retatrutide; magnitude and clinical significance being monitored in cardiovascular outcome trials

– **Skin hyperesthesia**: A less common adverse event not typically seen with GLP-1 monotherapy; its relationship to GCGR or GIPR activation is not yet mechanistically characterized³

• Discontinuation rates due to GI adverse events in Phase 2 ranged from approximately 16% to 19% in the highest dose groups — within the range documented for semaglutide and tirzepatide but not negligible

Potential Serious Adverse Effects Under Phase 3 Evaluation

Theoretical or signal-based risks require continued monitoring in larger, longer-duration trials:

– **Thyroid C-cell tumors**: A preclinical class concern for GLP-1R agonists based on rodent carcinogenicity studies; relevance to humans remains uncertain but triggers a contraindication in individuals with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN-2) — the same labeling requirement carried by all approved GLP-1 agonists²

– **Pancreatitis**: A rare but serious adverse event associated with the GLP-1 drug class; patients with a history of pancreatitis are excluded from TRIUMPH trials⁷

• Cardiovascular effects: The TRIUMPH CVOT will provide definitive MACE data; no signal of increased cardiovascular events was observed in Phase 2, but long-term data are critical given the trial population (obese adults with metabolic disease)

– **Lean mass loss**: Rapid, large-magnitude weight loss raises the clinically important question of body composition — specifically, whether retatrutide-induced weight loss disproportionately reduces lean body mass and bone density. Phase 3 protocols have incorporated body composition endpoints to address this directly¹

• Rebound weight gain upon discontinuation: Consistent with the GLP-1 drug class, weight regain is expected upon cessation of treatment — a significant practical consideration for long-term prescribing and health economics

Manufacturing Quality in the Unregulated Market

For retatrutide obtained outside of clinical trials through research chemical or peptide vendors:

• No cGMP manufacturing oversight applies; contamination with residual TFA (trifluoroacetic acid), heavy metals, endotoxins, and microbial load represent serious injection safety risks
• Product identity and potency cannot be independently verified; mislabeling, underdosing, and substitution with structurally similar but non-identical compounds are documented risks across the unregulated peptide market
• No pharmacovigilance system exists to capture adverse events from extra-clinical use

1. Katsi, V., et al. (2025). Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules, 15(6), 796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
2. Lilly Medical. (2025). What is the mechanism of action of retatrutide? https://medical.lilly.com/us/products/answers/what-is-the-mechanism-of-action-of-retatrutide-301926
3. Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 36(1). [Phase 1 data summarized in Katsi et al., PMC12190491]
4. Retatrutide — Structure and Pharmacology. https://en.wikipedia.org/wiki/Retatrutide
5. Rosenstock, J., et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet, 402(10401), 529–544. https://doi.org/10.1016/S0140-6736(23)01053-X
6. Jastreboff, A.M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
7. Eli Lilly and Company. (2025, December). Lilly’s Triple Agonist Retatrutide Delivered Weight Loss of Up to an Average of 71.2 lbs at 68 Weeks in Phase 3 TRIUMPH-4 Trial. Press Release. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-weight-loss-of-up-to-an-average-of-71-2-lbs
8. Free Medical Journals. (2026, May). Retatrutide FDA Approval Status 2026: Everything We Know So Far. https://freemedicaljournals.com/blog/retatrutide-fda-approval-status-2026/
9. Sanyal, A.J., et al. (2024). Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, decreases liver fat in people with metabolic dysfunction-associated steatotic liver disease: A Phase 2 randomized trial. Hepatology. [Summarized in Katsi et al., PMC12190491]
10. Guide to Pharmacology. Retatrutide — Ligand Page. https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=structure&ligandId=13769
11. NIH PubMed. Retatrutide for the treatment of obesity, obstructive sleep apnea and related conditions. (2026). https://pubmed.ncbi.nlm.nih.gov/41090431/
12. Rheumatology Advisor. (2025, December). TRIUMPH-4 Results: Retatrutide Cuts Weight and Knee OA Pain. https://www.rheumatologyadvisor.com/news/triumph-4-results-retatrutide-cuts-weight-and-knee-oa-pain/
13. Clinical Trials Arena. (2025, December). Lilly’s triple G agonist boasts 28.7% weight loss in Phase III TRIUMPH-4. https://www.clinicaltrialsarena.com/news/lilly-retatrutide-data-phase-iii-trial/

This content is for educational and research purposes only and does not constitute medical advice.

While sermorelin (as Geref®) was previously FDA-approved for pediatric growth hormone deficiency and diagnostic testing, the product was voluntarily discontinued in 2008 for commercial reasons.

Sermorelin is not currently available as an FDA-approved product in any country surveyed by comprehensive regulatory review.

A 2020 FDA-commissioned systematic review identified only 2 clinical trials meeting inclusion criteria—both examining diagnostic testing rather than therapeutic applications.

Current off-label therapeutic use occurs entirely through compounding pharmacies without supporting clinical trial evidence for body composition, anti-aging, or other common applications.

Subject matter experts acknowledge “limited outcomes-based human research” making it difficult to determine “the ideal combination and dose of medication to use, and the effects of long-term use.”

All products are intended strictly for laboratory research and development purposes only.